AR057745A1 - FORMULATIONS OF HFC DISSOLUTIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE - Google Patents

FORMULATIONS OF HFC DISSOLUTIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE

Info

Publication number
AR057745A1
AR057745A1 ARP060103518A ARP060103518A AR057745A1 AR 057745 A1 AR057745 A1 AR 057745A1 AR P060103518 A ARP060103518 A AR P060103518A AR P060103518 A ARP060103518 A AR P060103518A AR 057745 A1 AR057745 A1 AR 057745A1
Authority
AR
Argentina
Prior art keywords
salbutamol
formulations
hfc
citrate
hydrochloride
Prior art date
Application number
ARP060103518A
Other languages
Spanish (es)
Inventor
Friedrich Schmidt
Mariola Mann
Michael Cope
Holger Memmesheimer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR057745A1 publication Critical patent/AR057745A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones de disolucion para aerosol estabilizadas que contienen sales de adicion de ácido de salbutamol, que son adecuadas para su administracion por inhaladores de dosis medida (los MDI). Más en particular, formulaciones de una disolucion que contiene hidrocloruro de salbutamol o citrato de salbutamol, una de las dos sales mencionadas anteriormente en combinacion con una o más sustancias farmacologicamente activas adicionales, junto con un hidrofluorocarbono (HFC) medioambientalmente seguro como propelente, un disolvente conjunto, y un ácido inorgánico o un ácido orgánico.Stabilized aerosol solution formulations containing salbutamol acid addition salts, which are suitable for administration by metered dose inhalers (MDIs). More particularly, formulations of a solution containing salbutamol hydrochloride or salbutamol citrate, one of the two salts mentioned above in combination with one or more additional pharmacologically active substances, together with an environmentally safe hydrofluorocarbon (HFC) as a propellant, a solvent whole, and an inorganic acid or an organic acid.

ARP060103518A 2005-08-12 2006-08-11 FORMULATIONS OF HFC DISSOLUTIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE AR057745A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017599 2005-08-12

Publications (1)

Publication Number Publication Date
AR057745A1 true AR057745A1 (en) 2007-12-12

Family

ID=35564491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103518A AR057745A1 (en) 2005-08-12 2006-08-11 FORMULATIONS OF HFC DISSOLUTIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE

Country Status (6)

Country Link
US (1) US20070041911A1 (en)
AR (1) AR057745A1 (en)
PE (1) PE20070353A1 (en)
TW (1) TW200800141A (en)
UY (1) UY29740A1 (en)
WO (1) WO2007020204A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
ES2866175T3 (en) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Pharmaceutical composition
MY202069A (en) 2016-09-19 2024-03-31 Mexichem Fluor Sa De Cv Pharmaceutical composition
US11260052B2 (en) 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3515425B1 (en) 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol
JOP20200314A1 (en) * 2018-06-04 2020-12-06 Lupin Inc Stable pharmaceutical compositions for pressurized metered dose inhalers
FR3130554A1 (en) 2021-12-20 2023-06-23 Aptar France Sas Pharmaceutical composition comprising salbutamol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
EP1736147A3 (en) * 1991-06-10 2007-10-17 Schering Corporation Non-chlorofluorocarbon aerosol formulations
JP2003221335A (en) * 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
CN1216600C (en) * 2002-04-24 2005-08-31 信谊药厂 Levo-salbutamol hydrochloride aerosol and its prepn.
CN1228045C (en) * 2003-11-03 2005-11-23 王立强 Fast collapsed and fast dissolved preparation for oral cavity and producing method
GB0406069D0 (en) * 2004-03-17 2004-04-21 Thompson James Process

Also Published As

Publication number Publication date
UY29740A1 (en) 2007-03-30
PE20070353A1 (en) 2007-04-19
TW200800141A (en) 2008-01-01
WO2007020204A3 (en) 2007-06-07
US20070041911A1 (en) 2007-02-22
WO2007020204A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AR057745A1 (en) FORMULATIONS OF HFC DISSOLUTIONS CONTAINING SALBUTAMOL HYDROCHLORIDE OR SALBUTAMOL CITRATE
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
UY29562A1 (en) AMINO BENZOIL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
AR067309A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DERIVATIVES OF LIPOIC ACID
AR057180A1 (en) PHARMACEUTICAL FORMULATION OF ORAL ABSORPTION INCLUDING INSULIN, BETWEEN OTHERS, AND THE METHOD OF ADMINISTRATION
AR059359A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING PLECONARIL
UY30759A1 (en) CHEMICAL COMPOUNDS
CY1115150T1 (en) SOLUTION AID FOR ORAL SUPPLIES, WHICH CONTAIN DIGUANID
CL2008000442A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES.
BRPI0507225A2 (en) stable pharmaceutical solution formulations for pressurized metered dose inhalers
NO20080220L (en) Formulations with high drug loading and dosage forms
FR2949062B1 (en) NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
NI201500163A (en) COMPOSITIONS, METHODS AND SYSTEMS FOR THE DELIVERY VIA THE RESPIRATORY ROUTE OF THREE OR MORE ACTIVE AGENTS.
NO20082097L (en) Pharmaceutical compositions
CO6351721A2 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
AR060303A1 (en) SALM PHARMACEUTICAL FORMULATIONS OF 8- [1- (3,5 -BIS- (TRIFLUOROMETIL) PHENYL) -ETOXIMETILE] -8-PHENYL-1,7 -DIAZA-ESPIRO [4.5] DECAN -2- ONA AND TREATMENT METHODS USING SAME
NO20074854L (en) Pharmaceutical aerosol formulations for compressed, milled dose inhalers comprising a sequestering agent
DK2089008T3 (en) Formulations for delivery via pressurized metered dose inhalers comprising an essential oil as suspension stabilizer
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
NO20083759L (en) Dosage aerosols for administration of pharmaceutical compositions
UY29561A1 (en) DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
AR033596A1 (en) PHARMACEUTICAL COMPOSITION FOR INTRAMUSCULAR INJECTION CONTAINING LOXOPROPHENE
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid
CR9577A (en) PHARMACEUTICAL FORMULATIONS OF IMMEDIATE RELEASE AND WITH A LOAD OF HIGH DRUG (4-CHLOROPHENYL)
NO20064858L (en) New association between a heterocyclic compound and an antioxidant agent, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal